Figma Shares Indicated To Open $105/$110
Phillip Frost, CEO and Chairman of OPKO Health, Inc. (NASDAQ:OPK), has recently increased his stake in the company. According to a filing with the Securities and Exchange Commission, Frost acquired 100,000 shares of common stock on April 1, 2025, with the purchase price averaging $1.6485 per share. This transaction amounted to a total of $164,850. The purchase price aligns closely with the current market value of $1.66, with the stock trading near InvestingPro’s calculated Fair Value. The company maintains a healthy liquidity position with a current ratio of 3.43.
The shares were purchased by Frost Gamma Investments Trust, where Frost serves as the trustee. Following this acquisition, Frost now holds a total of 213,751,448 shares indirectly and 35,689,951 shares directly, reinforcing his position as a significant shareholder in OPKO Health, which currently has a market capitalization of $1.11 billion. InvestingPro analysis reveals that management has been actively buying back shares, with 8 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Opko Health reported its fourth-quarter 2024 earnings, exceeding expectations with an earnings per share (EPS) of $0.01 against a forecasted loss of $0.08. However, the company fell short on revenue, reporting $103.1 million compared to the anticipated $156.35 million. Despite the revenue miss, Opko Health turned a net income of $14 million, a significant improvement from the previous year’s net loss. In another development, Opko Health announced a collaboration with Entera Bio (NASDAQ:ENTX) to create an oral treatment for obesity, utilizing a dual agonist peptide. The partnership, which includes promising animal study data, aims to submit an Investigational New Drug application to the FDA later this year. Additionally, H.C. Wainwright reaffirmed its Buy rating on Opko Health with a $3.00 price target, following a strategic deal with Labcorp. This transaction involves Labcorp acquiring laboratory testing businesses from Opko’s subsidiary, BioReference Health, for a purchase price of $192.5 million. The deal is expected to close in the second half of 2025, with Opko possibly using proceeds to reduce debt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.